---
title: "Why CareDx's (NASDAQ:CDNA) Earnings Are Weaker Than They Seem"
description: "CareDx, Inc. (NASDAQ:CDNA) reported earnings that did not lead to a stock surge, raising investor concerns. The company's accrual ratio of 0.29 indicates that its free cash flow (FCF) was significantl"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/231446284.md"
published_at: "2025-03-12T00:16:09.000Z"
---

# Why CareDx's (NASDAQ:CDNA) Earnings Are Weaker Than They Seem

> CareDx, Inc. (NASDAQ:CDNA) reported earnings that did not lead to a stock surge, raising investor concerns. The company's accrual ratio of 0.29 indicates that its free cash flow (FCF) was significantly lower than its statutory profit, suggesting potential profitability issues. Despite a positive cash flow of $32 million, the dilution of shares by 7% impacts earnings per share (EPS). Additionally, unusual items boosted profit by $95 million, complicating the assessment of sustainable earnings. Analysts are cautious about future profitability, emphasizing the importance of EPS over net income for long-term growth.

We didn't see **CareDx, Inc's** (NASDAQ:CDNA) stock surge when it reported robust earnings recently. We decided to have a deeper look, and we believe that investors might be worried about several concerning factors that we found.

See our latest analysis for CareDx

## Zooming In On CareDx's Earnings

One key financial ratio used to measure how well a company converts its profit to free cash flow (FCF) is the **accrual ratio**. The accrual ratio subtracts the FCF from the profit for a given period, and divides the result by the average operating assets of the company over that time. You could think of the accrual ratio from cashflow as the 'non-FCF profit ratio'.

Therefore, it's actually considered a good thing when a company has a negative accrual ratio, but a bad thing if its accrual ratio is positive. While having an accrual ratio above zero is of little concern, we do think it's worth noting when a company has a relatively high accrual ratio. To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future".

Over the twelve months to December 2024, CareDx recorded an accrual ratio of 0.29. Unfortunately, that means its free cash flow was a lot less than its statutory profit, which makes us doubt the utility of profit as a guide. In fact, it had free cash flow of US$32m in the last year, which was a lot less than its statutory profit of US$52.5m. Given that CareDx had negative free cash flow in the prior corresponding period, the trailing twelve month resul of US$32m would seem to be a step in the right direction. However, that's not the end of the story. We must also consider the impact of unusual items on statutory profit (and thus the accrual ratio), as well as note the ramifications of the company issuing new shares. One positive for CareDx shareholders is that it's accrual ratio was significantly better last year, providing reason to believe that it may return to stronger cash conversion in the future. As a result, some shareholders may be looking for stronger cash conversion in the current year.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

In order to understand the potential for per share returns, it is essential to consider how much a company is diluting shareholders. CareDx expanded the number of shares on issue by 7.0% over the last year. As a result, its net income is now split between a greater number of shares. To talk about net income, without noticing earnings per share, is to be distracted by the big numbers while ignoring the smaller numbers that talk to *per share* value. Check out CareDx's historical EPS growth by clicking on this link.

## How Is Dilution Impacting CareDx's Earnings Per Share (EPS)?

CareDx was losing money three years ago. Zooming in to the last year, we still can't talk about growth rates coherently, since it made a loss last year. But mathematics aside, it is always good to see when a formerly unprofitable business come good (though we accept profit would have been higher if dilution had not been required). And so, you can see quite clearly that dilution is influencing shareholder earnings.

In the long term, if CareDx's earnings *per share* can increase, then the share price should too. But on the other hand, we'd be far less excited to learn profit (but not EPS) was improving. For that reason, you could say that EPS is more important that net income in the long run, assuming the goal is to assess whether a company's share price might grow.

## How Do Unusual Items Influence Profit?

The fact that the company had unusual items boosting profit by US$95m, in the last year, probably goes some way to explain why its accrual ratio was so weak. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. And that's as you'd expect, given these boosts are described as 'unusual'. We can see that CareDx's positive unusual items were quite significant relative to its profit in the year to December 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

## Our Take On CareDx's Profit Performance

CareDx didn't back up its earnings with free cashflow, but this isn't too surprising given profits were inflated by unusual items. Meanwhile, the new shares issued mean that shareholders now own less of the company, unless they tipped in more cash themselves. On reflection, the above-mentioned factors give us the strong impression that CareDx'sunderlying earnings power is not as good as it might seem, based on the statutory profit numbers. So while earnings quality is important, it's equally important to consider the risks facing CareDx at this point in time. Every company has risks, and we've spotted **2 warning signs for CareDx** you should know about.

In this article we've looked at a number of factors that can impair the utility of profit numbers, and we've come away cautious. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this **free** collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

If you're looking to trade CareDx, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Sponsored Content

### Related Stocks

- [CDNA.US - Caredex](https://longbridge.com/en/quote/CDNA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Zweig DiMenna Associates LLC 购入了 CareDx, Inc.的 348,400 股股票，股票代码为$CDNA | Zweig DiMenna Associates LLC 在第三季度将其在 CareDx, Inc. (NASDAQ:CDNA) 的持股增加了 153.8%，收购了 348,400 股，使其总持股达到 575,000 股，价值 836 万美 | [Link](https://longbridge.com/en/news/276125724.md) |
| Caredex｜8-K：2025 财年 Q4 营收 1.08 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/272266199.md) |
| 必和必拓利润飙升 30%，铜业务首次超越铁矿石成最大利润来源 | 全球市值最大的矿业公司必和必拓（BHP）因押注铜需求激增而获得回报，上半财年净利润同比增长近 30%。铜业务贡献了公司 51% 的基础息税折旧摊销前利润，首次超越其他业务成为最大利润来源。能源和汽车行业的强劲需求持续推高铜价，令这一转型的战 | [Link](https://longbridge.com/en/news/276092142.md) |
| 富兰克林电子｜10-K：2025 财年营收 21.31 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/276479931.md) |
| Paycom Software｜10-K：2025 财年营收 20.52 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276378587.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
